Generic User Fee Waivers Created In Draft House Bill, Breaking FDA-Industry Agreement

FDA says it likely will oppose the provision because it would create more administrative complexity and increase fees paid by individual firms, but many provider and professional associations think waivers could help prevent and alleviate drug shortages.